Research Areas

A Multicenter, Double-Blind, Randomized, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of An Investigational Medication Tablet Versus Atorvastatin in Patients With Hypercholesterolemia

Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination Investigational Medication, Administered Orally, Once Daily (QD) for 24 Months, Compared with Atorvastatin Alone, in Subjects with Mixed Hyperlipidemia

A Randomized, Placebo and Ezetimibe Controlled, Dose-Ranging Study to Evaluate Tolerability and Efficacy of An Investigational Subcutaneously Injected Medication on LDL-C in Hypercholesterolemic Subjects with a 10 year Framingham Risk Score of 10% or Less

A Randomized, Double-Blind, Active-Controlled, Multicenter, Crossover Study to Evaluate the Efficacy and Safety of A Fixed-Dose Combination Tablet Compared to Co-administration of Marketed Ezetimibe 10 mg and Atorvastatin 20 mg in Patients with Primary Hypercholesterolemia

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of An Investigational Medication Alone and With Atorvastatin

A Double-Blind, Randomized, Placebo -Controlled, Multicenter Study to Evaluate Long-Term Tolerability and Durable Efficacy of An Investigational Subcutaneously Injected Medication on LDL-C in Hypercholesterolemic Subjects

A Twelve-Week, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 0.5 QD, 1 mg QD and 1 mg BID of Alosertron in Female Subjects with Severe Diarrhea-Predominant IBS Who Have Failed Conventional Therapy

Efficacy and Safety of An Investigational Medication As Adjunctive Therapy for Refractory Partial Seizures in a Double Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre Clinical Trial

Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of An Investigational Medication Monotherapy in Subjects with Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs

A Historical-Controlled, Multicenter, Double-Blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to An Investigational Medication Monotherapy in Subjects with Partial-onset Seizures

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of An Investigational Medication in Subjects With Treatment-Resistant Partial Epilepsy

A Multicenter, Double-blind, Randomized, Parallel Group Study to Evaluate the Effects of an investigational medication on Microalbuminuria in Hypertensive Subjects with Type 2 Diabetes Mellitus (DM)

Double-Blind Comparison of the Efficacy and Safety of an Investigational Medication Versus Hydrochlorothiazide as add-on Therapy to Ramipril 10 MG QD in Diabetic Hypertensive Patients with Macroalbuminuria

Safety Evaluation of an investigational medication in Opioid Tolerant Patients

A Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Safety and Efficacy of an Investigational Medication and Duragesic in Subjects with Non-Malignant Pain

A Double-Blind, Randomized, Multicenter, Two-Part, Parallel-Group, Dose-Ranging Study of Twice-Daily and Once-Daily Investigational Medication in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease (COPD)

A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of An Investigational Inhalation Powder Once Daily Compared with Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD)

A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Trial of A Quarterly Subcutaneous Investigational Medication in the Prevention of Recurrent Cardiovascular Events Among Stable Post-Myocardial Infarction Patients With Elevated hsCRP

A Phase III, Randomized, Observer-Blind, Placebo-Controlled, Multicenter, Clinical Vaccination Trial to Assess the Prophylactic Efficacy, Safety, and Immunogenicity of An Investigational Vaccine When Administered Intramuscularly on a 0, 2-Month Schedule in Adults Aged ≥70 Years.

A Phase III, Randomized, Observer-Blind, Placebo-Controlled, Multicenter, Clinical Vaccination Trial to Assess the Prophylactic Efficacy, Safety, and Immunogenicity of An Investigational Vaccine When Administered Intramuscularly on a 0, 2-Month Schedule in Adults aged 50 Years and Older.